TrialThe Journal of urology2026

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.

Neal D Shore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.